Here’s what you should know:
1. The company’s GAAP adjusted earnings were $432 million or $0.31 per share.
2. Boston Scientific Chairman CEO Mike Mahoney said in a statement, “Our strong results reflect our global team’s focused efforts to execute our category leadership strategy and advance the standard of care. Through internal research and tuck-in acquisitions, we continue to bring meaningful innovations to market, enabling our customers to deliver life-changing care to millions of patients around the world.”
3. Boston Scientific’s endoscopy division increased sales from $403 million to $443 million.
4. The cardiovascular division led the quarter with $908 million in sales, up from $857 million.
5. Despite the strong quarter, Boston Scientific lowered its full-year guidance to between $9.79 billion and $9.83 billion. It was previously between $9.8 billion and $9.88 billion.
More articles on gastroenterology:
Enterome & Takeda to co-develop drug for Crohn’s disease: 5 insights
Dr. Richard Blumberg earns spot in National Academy of Medicine — 3 insights
Central Maine Healthcare adds medical director in Dr. Sean McGarr — 4 insights
